Metastatic Adenocarcinoma
🧬 Metastatic Adenocarcinoma
Metastatic adenocarcinoma arises when glandular cancers spread to distant organs via blood or lymphatics.
⚠️ They account for a large proportion of metastatic tumours, complicating treatment and prognosis.
Early detection is critical.
🔎 Common Primary Sources
- 🫁 Lung: Spreads to liver, bones, brain, adrenals.
- 🦴 Thyroid: Papillary/follicular → lungs, bones.
- 🍽️ Gut: Oesophagus (Barrett’s), stomach, colorectal → liver, peritoneum.
- 👩🦰 Ovarian/Uterine: Spread to peritoneum, lungs, liver, nodes.
- 🩺 Pancreas: Aggressive, late presentation → liver, peritoneum.
- 🎗️ Breast: Ductal/lobular → bone, liver, lungs, brain.
- 🧾 Adrenal/Parathyroid: Rare but can metastasize widely.
- 🩸 Renal cell carcinoma: (not classic adenocarcinoma but similar spread) → lungs, bones, liver, brain.
🚫 Common Cancers Not Typically Adenocarcinoma
- Bladder: Transitional cell carcinoma (TCC). Rare adenocarcinoma subtype exists.
- Larynx: Squamous cell carcinoma (SCC), smoking/alcohol related.
- Cervix: Mostly SCC (HPV-linked), though adenocarcinoma occurs in some cases.
🧪 Diagnostic Approach
- Biopsy & Histopathology: Gold standard, IHC to suggest tissue of origin.
- Imaging: CT, MRI, PET for mapping spread.
- Blood Markers: e.g., CA-125 (ovarian), CEA (colorectal), PSA (prostate differential).
💊 Treatment Options
- 🔪 Surgery: Occasionally for isolated/oligometastatic disease.
- 💉 Chemotherapy: Systemic therapy is cornerstone for widespread disease.
- 🎯 Targeted Therapy: EGFR, ALK, HER2, KRAS inhibitors depending on mutation profile.
- ☢️ Radiotherapy: Local control & symptom palliation (e.g., bone/brain mets).
- 🛡️ Immunotherapy: Checkpoint inhibitors (e.g., PD-1/PD-L1 blockade) increasingly used in lung, GI, and renal adenocarcinomas.
📚 Clinical Pearls
- 🧬 Always consider adenocarcinoma of unknown primary (CUP) when biopsy shows glandular histology but no clear source.
- 💡 Lung, colorectal, pancreas, and breast are the most frequent culprits in adults.
- ⚠️ Paraneoplastic syndromes may provide diagnostic clues (e.g., hypercoagulability in pancreatic adenocarcinoma).
- 🧾 Prognosis depends on primary site, burden of metastases, and available targeted therapies.